Turning FDA and FCC Filings Into an Early Buying Signal

An FDA 510(k) clearance or premarket approval (PMA) means FDA has authorized a specific device to be legally marketed in the US for its stated intended use. An FCC equipment authorization means a piece of hardware has passed the testing required before it can be sold in the US. Neither filing guarantees the company has funding lined up to launch at scale, or a firm date, but both are concrete, verifiable evidence that a real product reached a real regulatory milestone, which is more than most buying signals offer.

The FDA maintains a public device database searchable by company name or product code, and the FCC's equipment authorization search covers filings by applicant. Both are free, require no login, and update on a public schedule, which makes them one of the more reliable sources to build a recurring check around, unlike a press mention that might never come or a job posting that could mean several different things entirely.

Companies typically ramp hiring, marketing spend, and operational buildout in the weeks after a clearance or authorization lands, since the regulatory gate was often the thing blocking a launch timeline. That ramp-up window is when a company is actually receptive to a new operational tool or service, since they're actively scaling something rather than running steady-state. A filing from a long stretch ago, with no visible follow-up activity since, is a weaker signal than a recent one, and it's worth checking job postings or press mentions for that same company to see whether the ramp-up ever actually happened before treating an old filing as still relevant.

A filing usually lists a regulatory contact or an agent who handled the submission, and that person is often not the buyer for an operational or sales tool. Use the filing to identify the company and the timing, then find the actual decision-maker, likely someone in operations, product, or commercial leadership, through your normal contact-finding process rather than reaching out to whoever's name happens to appear on the filing itself. Confirming the right title before sending anything matters more here than with most signals, since the filing's contact field is often a law firm or a regulatory consultant with no involvement in the company's day-to-day purchasing at all.

A clearance or authorization doesn't tell you the company has secured funding for a full commercial launch, doesn't tell you a firm ship date, and doesn't tell you the product will actually reach the market rather than stall afterward for unrelated reasons. Frame outreach around the fact that the company reached this specific, verifiable milestone, not around assumptions about their timeline or budget that the filing itself doesn't support.

A single search run once tells you what's true today and nothing about what's coming next month. Set a recurring check against your target product categories or applicant names, on a schedule tight enough to catch a fresh filing while the post-clearance ramp-up window is still open. Treat a new match the same way you'd treat any other fresh trigger event, worth flagging for a rep promptly rather than sitting in a report nobody reads until the next quarterly review. Assign ownership of that recurring check to one specific person, since a task with no clear owner tends to quietly stop happening after the first month or two.

A simple recurring check works like this:

1. List the product categories and applicant names that match the customers you actually sell to, so every search covers companies worth pursuing.
2. Search the FDA device database and the FCC equipment authorization search on a fixed schedule, since both are free and update publicly.
3. Flag each new match as a trigger event, noting the filing type, the company, and the date it appeared.
4. Find the real decision-maker in operations, product, or commercial leadership instead of writing to the regulatory contact named on the filing.
5. Reach out while the post-clearance ramp-up window is still open, framing the message around the milestone rather than assumptions about funding or ship dates.